Peptide Comparison
Cartalax vs Thymagen
Editorial breakdown of mechanism, evidence, decision criteria, and the misconceptions worth calling out.
Data-derived verdict
Cartalax and Thymagen share the khavinson class and carry roughly equivalent evidence (Russian Research / Russian Research). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.
Evidence at a glance
FDA-approved Phase 3 Phase 2 / approved abroad Anecdotal + animal Preclinical / flagged
Shared safety considerations
Both compounds share these reported concerns: limited western evidence. Open each peptide page for the full risk paragraph and source citations.
Side-by-side
| Cartalax | Thymagen | |
|---|---|---|
| Class | Khavinson short peptide bioregulator | Khavinson short peptide bioregulator |
| Drug class | Longevity | Immune |
| Mechanism | Tissue-specific gene expression modulation in chondrocytes | Thymic gene expression modulation |
| Route | Oral | Oral / Intranasal |
| Half-life | Short (minutes) | Short (minutes) |
| Dosage (research) | Oral capsule 1-2x daily | Oral capsule 1-2x daily |
| Evidence tier | Russian Research | Russian Research |
| Research depth | 2 indexed | 1 indexed |
| Availability | Research | Research |
| Reported risks | Limited Western evidence | Limited Western evidence |
Reported research data only. "Studied for" and "reported in literature" describe published research focus, not clinical recommendation. Most peptides catalogued here are not FDA-approved for human use.
Frequently asked questions
Should I pick Cartalax or Thymagen?
Cartalax and Thymagen share the khavinson class and carry roughly equivalent evidence (Russian Research / Russian Research). The catalogued data does not favor one over the other; pick based on practical fit: route, dosing schedule, cost, regulatory framing, or which specific receptor sub-target matters most for the intended research use.
What is the difference between Cartalax and Thymagen?
Cartalax is classed as Khavinson short peptide bioregulator; Thymagen is classed as Khavinson short peptide bioregulator. Reported mechanism: Cartalax, Tissue-specific gene expression modulation in chondrocytes; Thymagen, Thymic gene expression modulation. Reported half-life: Cartalax, Short (minutes); Thymagen, Short (minutes). Routes in published studies: Cartalax, Oral; Thymagen, Oral / Intranasal.
Which has stronger evidence, Cartalax or Thymagen?
Cartalax and Thymagen sit on the same rung of PeptideHelper.org's five-step evidence scale, which runs from preclinical to FDA-approved. Cartalax is graded Russian Research, with 2 cited sources on its reference page and 2 indexed studies. Thymagen is graded Russian Research, with 2 cited sources on its reference page and 1 indexed studies.
Which is more accessible, Cartalax or Thymagen?
Neither Cartalax nor Thymagen is an FDA-approved drug. Catalog status: Cartalax, Research; Thymagen, Research.
Are Cartalax and Thymagen ever combined?
Cartalax and Thymagen appear together in no stack catalogued on PeptideHelper.org, and the interaction engine raises no flag for the pair.
Open the PeptideHelper.org compare tool to add more compounds to this side-by-side and filter by evidence tier interactively.
Loading interactive view…